IRIS
PASQUINUCCI, Lorella Giuseppina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.798
EU - Europa 4.065
AS - Asia 3.671
AF - Africa 601
SA - Sud America 564
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 1
Totale 16.713
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.558
SG - Singapore 1.779
IT - Italia 1.301
RU - Federazione Russa 1.225
CN - Cina 1.011
BR - Brasile 459
IE - Irlanda 413
CI - Costa d'Avorio 307
UA - Ucraina 282
VN - Vietnam 269
FR - Francia 197
KR - Corea 188
DE - Germania 187
CA - Canada 173
SN - Senegal 118
GB - Regno Unito 108
NG - Nigeria 79
IN - India 73
ES - Italia 62
JP - Giappone 59
BD - Bangladesh 54
FI - Finlandia 48
NL - Olanda 43
HK - Hong Kong 41
PL - Polonia 41
SE - Svezia 41
MX - Messico 40
ID - Indonesia 37
ZA - Sudafrica 33
AR - Argentina 28
IQ - Iraq 26
TR - Turchia 26
BE - Belgio 20
UZ - Uzbekistan 19
EC - Ecuador 18
VE - Venezuela 16
AT - Austria 15
KE - Kenya 15
CH - Svizzera 14
BJ - Benin 13
CL - Cile 13
AE - Emirati Arabi Uniti 12
AU - Australia 12
CZ - Repubblica Ceca 12
PK - Pakistan 12
LT - Lituania 11
CO - Colombia 10
CR - Costa Rica 10
GR - Grecia 10
IR - Iran 10
MA - Marocco 10
HU - Ungheria 8
LB - Libano 8
TN - Tunisia 8
JM - Giamaica 7
PY - Paraguay 7
DZ - Algeria 6
EG - Egitto 6
IL - Israele 6
SA - Arabia Saudita 6
PE - Perù 5
RS - Serbia 5
AZ - Azerbaigian 4
BG - Bulgaria 4
NP - Nepal 4
OM - Oman 4
UY - Uruguay 4
AL - Albania 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
JO - Giordania 3
KZ - Kazakistan 3
MY - Malesia 3
TH - Thailandia 3
BB - Barbados 2
DK - Danimarca 2
ET - Etiopia 2
GE - Georgia 2
HR - Croazia 2
LV - Lettonia 2
PA - Panama 2
PH - Filippine 2
PS - Palestinian Territory 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
EU - Europa 1
GY - Guiana 1
IM - Isola di Man 1
KG - Kirghizistan 1
LY - Libia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
Totale 16.710
Salva come PNG Salva come JPEG
Città #
Dallas 1.810
Singapore 1.051
Santa Clara 791
Chandler 583
Moscow 538
Houston 481
San Jose 451
Ashburn 432
Dublin 410
Catania 375
Chicago 338
Abidjan 307
Jacksonville 282
Hefei 229
Boardman 187
Seoul 187
Beijing 164
Los Angeles 132
Lauterbourg 125
Dakar 118
Nanjing 115
Cambridge 109
Andover 108
Lawrence 108
Toronto 99
Civitanova Marche 98
Council Bluffs 92
Ho Chi Minh City 81
New York 77
Rome 64
Bremen 60
São Paulo 57
Buffalo 56
Wilmington 56
Hanoi 51
Des Moines 50
Tokyo 50
San Mateo 47
The Dalles 45
Columbus 39
Lagos 39
Naples 38
Hong Kong 37
Grafing 35
Munich 35
Shenyang 35
Nanchang 33
Saint Petersburg 32
Warsaw 32
Abuja 29
Montreal 28
Denver 27
London 27
Messina 27
Atlanta 26
Changsha 26
Orem 26
Jiaxing 25
Brooklyn 24
Ottawa 24
Milan 23
Johannesburg 22
Hebei 21
Poplar 21
Frankfurt am Main 20
Helsinki 20
Amsterdam 19
Brussels 19
Jakarta 19
Rio de Janeiro 18
Tianjin 18
Da Nang 17
Pune 17
Chennai 16
Palermo 16
Falls Church 15
Phoenix 15
Haiphong 14
Lappeenranta 14
Madrid 14
Paris 14
San Giovanni la Punta 14
Seattle 14
Tashkent 14
Turku 14
Cotonou 13
Mexico City 13
San Francisco 13
Belo Horizonte 12
Marseille 12
San Gregorio di Catania 12
Dong Ket 11
Port Harcourt 11
Stockholm 11
Augusta 10
Baghdad 10
Ningbo 10
Norwalk 10
Pozzallo 10
Ankara 9
Totale 11.653
Salva come PNG Salva come JPEG
Nome #
Targeting histone deacetylase 1: Inhibition and activation as promising therapeutic strategies for diverse disorders 434
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation 411
((2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist 320
The simultaneous activation of μ- and δ-opioid receptors by (−)-2S-LP2 rescues allodynia with the contribution of TGF-β1 signaling in a rat chronic constriction injury model 226
Antioxidant properties and pharmacokinetic studies of new selective σ1 bifunctional ligands 205
Neuroprotective effects of Rosmarinus officinalis L. extract in oxygen glucose deprivation (OGD)-injured human neural-like cells 202
Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells 197
Do vitamins halt the COVID-19-evoked pro-inflammatory cytokines involved in the development of neuropathic pain? 194
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 194
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 185
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review 184
Caspase-3 activation in human melanoma A375 cell line by a novel selective sigma-2 agonist 176
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 168
(+)-cis-N-ethyleneamino-N-normetazocine derivatives. Novel and selective sigma ligands with antagonist properties 164
ANTIALLODINIC AND ANTIHYPERALGESIC EFFECTS OF LP1, AN OPIOID MULTITARGET LIGAND, IN INFLAMMATORY AND NEUROPATHIC PAIN STATES 160
Benzomorphan-based opioid ligands with mixed m agonist/d antagonist activity 159
R- ed S-LP2: sintesi, molecular docking e valutazione farmacologica 157
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review 155
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma 155
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 152
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. 151
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 151
Intercellular communication and ion channels in neuropathic pain chronicization 146
Dual MOR/DOR agonist benzomorphan-based compounds for pain relief 145
Sigma-1 Receptor Inhibition Reduces Mechanical Allodynia and Modulate Neuroinflammation in Chronic Neuropathic Pain 144
Development of novel LP1-based analogues with enhanced delta opioid receptor profile 143
Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands 141
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling 140
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 139
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation 138
Design of Small Molecules for Oncological and Neurodegenerative Diseases 137
Design and Synthesis of Tetrahydropyrrolo[3,4‐c]Pyrazole Sigma‐1 Receptor Ligands 135
MOR/DOR targeting: an useful strategy in pain management 135
A New LP1 analogue is used to better understand MOR ligand Binding Domain and its mechanisms of activation 133
Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 133
From plant to bench: natural products as source for analgesic drug development. 133
Analgesici oppioidi: nuove opportunità nella terapia del dolore 132
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 131
Dual-target ligands and pain: our experience 130
An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain 130
LP2 e 2S-LP2: agonisti biased dual target MOR/DOR nel trattamento del dolore cronico 130
Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain 130
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation. 129
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 128
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain 128
Design and synthesis of trans-decahydroisoquinoline derivatives as new tramadol-like ligands 128
Bivalent opioid peptides synthesized from μ selective monomers display preferential selectivity for δ receptors 128
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 127
Correction to Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 125
In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate 123
Novel sigma 1-antagonists with cis-(+)-normetazocine scaffold: synthesis, molecular modeling, and antinociceptive effect 122
Antiallodinic and antihyperalgesic effects of LP1, an opioid multitarget ligand, in inflammatory and neurophatic pain states 122
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 121
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management 117
From Plant to Chemistry: Sources of Antinociceptive Non-Opioid Active Principles for Medicinal Chemistry and Drug Design 115
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands 115
Discovery of AD258 as a Sigma Receptor Ligand with Potent Antiallodynic Activity 115
Analgesici oppioidi 115
Design, Synthesis and biological evaluation of hybrid MOR agonist/ HDACi molecules as potential therapeutic agents for chronic pain treatment 114
Analoghi non-peptidici della dinorfina A(1-8): progettazione, sintesi e valutazione farmacologica di agonisti ad elevata selettività Kappa. 114
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment 113
Design, synthesis and biological evaluation of MOR agonist/HDACi hybrid compounds: a new potential therapeutic strategy for persistent pain management 112
Synthesis of (+)-(1'R,2'S) and (1'S,2'R)-6,11 -dimethyl-1,2,3,4,5,6-hexahydro-3-[[2'-(alkoxycarbonyl)-2'- phenylcycloprophy]methyl]-2,6-methano-3-benzazocin-8-ol. Comparison of the affinities for sigma(1) and opioid receptors with in the diastereoisomeric MPCB and CCB 111
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 111
THE BENZOMORPHAN-BASED COMPOUND LP1 AS A MULTITARGET OPIOID LIGAND FOR CHRONIC PAIN TREATMENT 110
CCB, a novel specific kappa opioid agonist, which discriminates between opioid and sigma 1 recognition sites 110
Multitarget opioid ligands in pain relief: New players in an old game 109
The benzomorphan-based compound LP1 is a central acting MOR agonist/DOR antagonist suitable for chronic pain treatment 109
Substituted 1-phenyl-2-cyclopropylmethylamines with high affinity and selectivity for sigma sites 109
Progress in the development of more effective and safer analgesics for pain management 109
In-vitro evaluation of a new benzomorphan-based ligand 107
Evaluation of N-substituent structural variations in opioid receptor profile of LP1. 107
Designing drugs optimized for both blood-brain barrier permeation and intra-cerebral partition 106
DESIGN, SYNTHESIS, MOLECULAR MODELING AND PHARMACOLOGICAL EVALUATION OF NOVEL DIAZABICYCLO[4.3.0]NONANE AND 2,7-DIAZASPIRO[3.5]NONANE AS SIGMA RECEPTORS LIGANDS 104
Non-peptide ligands for opioid receptors. Design of kappa-specific agonists 104
Hybrid MOR agonist/HDACi molecules as potential antinociceptive multi-target drugs: design, synthesis, and biological evaluation 103
The Benzomorphan-Based Compound LP1 as Suitable Candidate for Pain Management 103
Evaluation of N-substitution in 6,7-benzomorphan compounds 102
CCB - A novel analog of MPCB with high binding affinity and specific kappa opioid receptor agonist 102
Rosemary Essential Oil-Loaded Lipid Nanoparticles: In Vivo Topical Activity from Gel Vehicles 101
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 101
Investigation of Tau-Dependent Epigenetic Reprogramming in Alzheimer’s Disease 100
Nonpeptide Analogues of Dynorphin A(1-8): Design, Synthesis, and Pharmacological Evaluation of k-Selective Agonists 100
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures 98
Differential scanning calorimetry approach to investigate the transfer of the multitarget opioid analgesic LP1 to biomembrane model 98
New developments in opioid receptors ligands 97
From agonist to antagonist profile in LP1 analogues through the introduction of different N-substituents in benzomorphan-based ligands 96
Idebenone: Novel strategies to improve its systemic and local efficacy 96
Synthesis and structure-activity relationships of (–)-cis-N-normetazocine-based LP1 derivatives 96
Enhancing HDAC Inhibitor Screening: Addressing Zinc Parameterization and Ligand Protonation in Docking Studies 95
Design, Synthesis, and Evaluation of Novel (−)‐cis‐N‐Normetazocine Derivatives: In Vitro and Molecular Modeling Insights 94
Synthesis, Computational Insights, and Evaluation of Novel Sigma Receptors Ligands 94
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics for Pain Treatment 93
NOVEL N-NORMETAZOCINE DERIVATIVES WITH SIGMA-1 RECEPTOR ANTAGONIST PROFILE AS POTENTIAL ANALGESICS FOR INFLAMMATORY PAIN MANAGEMENT 93
Synthesis and Pharmacological Evaluation of Peptidomimetic of the Kappa-Opioid Receptors 93
Multitarget opioid ligands as suitable candidates for pain management Pharmacolgical fingerprint of the benzomorphan-based opioid compound LP1 91
Simultaneous activation of mu and delta opioid receptors reduces allodynia and astrocytic connexin 43 in an animal model of neuropathic pain 91
SYNTHESIS, COMPUTATIONAL INSIGHTS, AND EVALUATION OF NOVEL SIGMA RECEPTORS LIGANDS 90
PET imaging of the opioid system using radioligands: Synthetic approaches and translational applications 90
Sigma-1 receptor targeting inhibits connexin 43 based intercellular communication in chronic neuropathic pain 90
Totale 13.449
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.923
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.923
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021147 0 0 0 0 0 0 0 0 0 0 112 35
2021/2022927 99 104 9 24 134 11 119 33 84 26 36 248
2022/20231.755 139 95 29 238 131 263 6 341 359 34 80 40
2023/20241.080 55 136 51 40 56 258 67 108 8 30 185 86
2024/20253.374 83 516 150 226 662 424 229 134 218 260 224 248
2025/20267.858 470 387 2.036 506 1.059 1.411 788 199 418 448 136 0
Totale 17.052